JP2019507180A - がんに対する組合せ療法 - Google Patents

がんに対する組合せ療法 Download PDF

Info

Publication number
JP2019507180A
JP2019507180A JP2018546596A JP2018546596A JP2019507180A JP 2019507180 A JP2019507180 A JP 2019507180A JP 2018546596 A JP2018546596 A JP 2018546596A JP 2018546596 A JP2018546596 A JP 2018546596A JP 2019507180 A JP2019507180 A JP 2019507180A
Authority
JP
Japan
Prior art keywords
seq
checkpoint
cells
ido
immunotherapeutic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018546596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507180A5 (enExample
Inventor
アンデルセン，マッズ，ハルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1603805.1A external-priority patent/GB201603805D0/en
Priority claimed from GBGB1610018.2A external-priority patent/GB201610018D0/en
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Publication of JP2019507180A publication Critical patent/JP2019507180A/ja
Publication of JP2019507180A5 publication Critical patent/JP2019507180A5/ja
Priority to JP2022027569A priority Critical patent/JP7417645B2/ja
Priority to JP2024000506A priority patent/JP7785817B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018546596A 2016-03-04 2017-03-03 がんに対する組合せ療法 Pending JP2019507180A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022027569A JP7417645B2 (ja) 2016-03-04 2022-02-25 がんに対する組合せ療法
JP2024000506A JP7785817B2 (ja) 2016-03-04 2024-01-05 がんに対する組合せ療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1603805.1 2016-03-04
GBGB1603805.1A GB201603805D0 (en) 2016-03-04 2016-03-04 Combination
GB1610018.2 2016-06-08
GBGB1610018.2A GB201610018D0 (en) 2016-06-08 2016-06-08 Combination
PCT/EP2017/055093 WO2017149150A1 (en) 2016-03-04 2017-03-03 Combination therapy against cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022027569A Division JP7417645B2 (ja) 2016-03-04 2022-02-25 がんに対する組合せ療法

Publications (2)

Publication Number Publication Date
JP2019507180A true JP2019507180A (ja) 2019-03-14
JP2019507180A5 JP2019507180A5 (enExample) 2020-04-09

Family

ID=58231605

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018546596A Pending JP2019507180A (ja) 2016-03-04 2017-03-03 がんに対する組合せ療法
JP2022027569A Active JP7417645B2 (ja) 2016-03-04 2022-02-25 がんに対する組合せ療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022027569A Active JP7417645B2 (ja) 2016-03-04 2022-02-25 がんに対する組合せ療法

Country Status (13)

Country Link
US (2) US20190343940A1 (enExample)
EP (2) EP3423087B1 (enExample)
JP (2) JP2019507180A (enExample)
DK (1) DK3423087T3 (enExample)
ES (1) ES2965009T3 (enExample)
FI (1) FI3423087T3 (enExample)
HR (1) HRP20240052T1 (enExample)
HU (1) HUE064857T2 (enExample)
LT (1) LT3423087T (enExample)
PL (1) PL3423087T3 (enExample)
PT (1) PT3423087T (enExample)
SI (1) SI3423087T1 (enExample)
WO (1) WO2017149150A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510301A (ja) * 2021-03-17 2024-03-06 アイオー バイオテック エーピーエス がんのための併用療法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107849144B (zh) 2015-05-29 2021-09-17 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
MA43163A (fr) 2015-11-02 2018-09-12 Five Prime Therapeutics Inc Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
JP2020517913A (ja) 2017-04-28 2020-06-18 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドによる治療方法
UA128472C2 (uk) 2017-08-25 2024-07-24 Файв Прайм Терапеутікс Інк. B7-h4 антитіла і методи їх використання
WO2019102265A1 (en) 2017-11-23 2019-05-31 Theraphage Inc. Peptide displaying bacteriophage nanoparticles and related compositions and methods
WO2019101954A1 (en) * 2017-11-24 2019-05-31 Io Biotech Aps Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc)
BR112020016986A2 (pt) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. formulações de anticorpo contra b7-h4
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
KR102653960B1 (ko) * 2020-07-23 2024-04-03 의료법인 성광의료재단 암 치료를 위한 면역체크포인트 억제제의 병용 요법
WO2022184930A2 (en) 2021-03-05 2022-09-09 Universität Basel Compositions for the treatment of ebv associated diseases or conditions
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
US20240245730A1 (en) * 2021-05-17 2024-07-25 Wisconsin Alumni Research Foundation Synthetic protein for inducing immune tolerance
JP2025507571A (ja) * 2022-02-18 2025-03-21 モデルナティエックス インコーポレイテッド チェックポイントがんワクチンをコードするｍＲＮＡ及びその使用
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055111A1 (en) * 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
JP2014534202A (ja) * 2011-10-17 2014-12-18 ヘルレフ ホスピタルＨｅｒｌｅｖ Ｈｏｓｐｉｔａｌ Ｐｄ−ｌ１に基づく免疫療法
WO2015119944A1 (en) * 2014-02-04 2015-08-13 Incyte Corporation Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
HUE037973T2 (hu) * 2008-04-17 2018-09-28 Io Biotech Aps Indolamin-2,3-dioxigenáz-alapú immunterápia
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
WO2015181343A2 (en) * 2014-05-30 2015-12-03 Ventana Medical Systems, Inc. Multiplex assay for improved scoring of tumor tissues stained for pd-l1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055111A1 (en) * 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
JP2014534202A (ja) * 2011-10-17 2014-12-18 ヘルレフ ホスピタルＨｅｒｌｅｖ Ｈｏｓｐｉｔａｌ Ｐｄ−ｌ１に基づく免疫療法
WO2015119944A1 (en) * 2014-02-04 2015-08-13 Incyte Corporation Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510301A (ja) * 2021-03-17 2024-03-06 アイオー バイオテック エーピーエス がんのための併用療法

Also Published As

Publication number Publication date
EP4316517A3 (en) 2024-05-29
HUE064857T2 (hu) 2024-04-28
EP4316517A2 (en) 2024-02-07
EP3423087A1 (en) 2019-01-09
WO2017149150A1 (en) 2017-09-08
HRP20240052T1 (hr) 2024-03-29
DK3423087T3 (da) 2023-12-18
JP2022068348A (ja) 2022-05-09
JP7417645B2 (ja) 2024-01-18
EP3423087B1 (en) 2023-11-15
JP2024045180A (ja) 2024-04-02
PT3423087T (pt) 2023-12-28
US20220257741A1 (en) 2022-08-18
LT3423087T (lt) 2024-01-25
US20190343940A1 (en) 2019-11-14
PL3423087T3 (pl) 2024-05-20
SI3423087T1 (sl) 2024-03-29
FI3423087T3 (fi) 2023-12-15
ES2965009T3 (es) 2024-04-10

Similar Documents

Publication Publication Date Title
JP7417645B2 (ja) がんに対する組合せ療法
US12331097B2 (en) T cell receptor constructs and uses thereof
Keenan et al. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice
Sommershof et al. Chronic stress suppresses anti-tumor TCD8+ responses and tumor regression following cancer immunotherapy in a mouse model of melanoma
JP2022027785A (ja) Ａｄｔとアンドロゲン受容体ワクチンとの組合せ療法
WO2005002621A2 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
JP2005523277A (ja) 癌の治療
Kitagawa et al. Preclinical development of a WT1 oral cancer vaccine using a bacterial vector to treat castration-resistant prostate cancer
KR20240042414A (ko) 흑색종의 치료용 조성물 및 방법
CN117529551A (zh) 表达嵌合抗原受体的病毒特异性免疫细胞
JP6654207B2 (ja) 短鎖ペプチド抗腫瘍ワクチンを用いて早期のｔメモリー応答を誘発する方法。
Ishii et al. A combination of check-point blockade and α-galactosylceramide elicits long-lasting suppressive effects on murine hepatoma cell growth in vivo
JP7785817B2 (ja) がんに対する組合せ療法
JP2021504336A (ja) 抗体依存性細胞媒介性細胞傷害（ａｄｃｃ）の強化
HK40106688A (en) Combination therapy against cancer
EP2661622A1 (en) Bystander immune suppression as a predictor for response to a vaccine
KR20200093005A (ko) 암의 향상된 치료
CA2990893C (fr) Peptides immunogenes de preprocalcitonine
EP4048780A1 (en) Adoptive immunotherapy
US20240307516A1 (en) Combination therapy for cancer
Huete-Carrasco et al. Adsorption of antigen to polymeric nanoparticles enhances cytotoxic T cell responses and anti-tumour immunity by targeting conventional type 1 dendritic cells.
JP2024536152A (ja) サバイビンおよびｍａｇｅ－ａ９二重標的化免疫療法
Gleisner Muñoz et al. A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth
Sultan The Role of Signal 3 Cytokines in Enhancing the Antitumor Effects of Peptide-Based Vaccines
EA041118B1 (ru) Способ индукции раннего ответа т-клеток памяти противоопухолевой вакциной из коротких пептидов

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211026